Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹0 Cr.
Stock P/E
—
P/B
2.5
Current Price
₹89.7
Book Value
₹ 35.5
Face Value
10
52W High
₹156.4
52W Low
₹ 50.1
Dividend Yield
0%

Nephro Care India Overview

Business

Nephro Care India Ltd. is a specialized healthcare provider primarily focused on comprehensive kidney care. The company offers a range of services including dialysis (hemodialysis and peritoneal dialysis), nephrology consultations, preventive kidney care, and potentially related diagnostic and pharmaceutical services. Its core business model revolves around operating dialysis centers and clinics, providing essential treatment for chronic kidney disease patients. The company generates revenue through patient fees for dialysis sessions, consultations with nephrologists, and other associated medical procedures and services.

Revenue Mix

The company's primary and overwhelmingly dominant segment is nephrology and dialysis services. Given its specialized name and focus, almost all revenue is derived from this specific area of healthcare. Detailed revenue contribution from sub-segments (e.g., hemodialysis vs. peritoneal dialysis, outpatient consultations vs. procedures) is not publicly disclosed, but kidney care remains the singular focus.

Industry

The company operates within the specialized segment of India's Hospital & Healthcare Services sector, specifically kidney care. The Indian healthcare industry is experiencing significant growth driven by increasing prevalence of lifestyle diseases (like diabetes and hypertension, which are major causes of kidney disease), an aging population, rising healthcare awareness, and improving access to medical facilities. Nephro Care positions itself as a specialized player, often competing with large multi-specialty hospitals that have nephrology departments, as well as other standalone dialysis chains (both regional and national). Its specialization allows it to focus clinical expertise and potentially offer a more dedicated patient experience.

MOAT

Specialized Expertise: Focused dedication to nephrology allows for deeper clinical expertise, standardized protocols, and potentially better patient outcomes, building a strong reputation within the niche.

Network Effect (emerging): As it expands its network of dialysis centers, particularly in underserved regions, it can create convenience and accessibility for patients, making it a preferred choice due to proximity and established trust.

Switching Costs: For chronic conditions requiring regular, lifelong treatment like dialysis, patients often develop strong relationships with their care providers and find it inconvenient to switch due to established routines, proximity, and familiarity with staff and doctors.

Brand Reputation: Building a specialized brand in kidney care can instill patient confidence, attracting those seeking dedicated and high-quality treatment.

Growth Drivers

Rising Prevalence of Kidney Disease: The increasing incidence of lifestyle diseases like diabetes and hypertension significantly contributes to the growing patient pool requiring dialysis.

Aging Population: A higher proportion of the elderly population leads to a greater demand for specialized medical services, including kidney care.

Expansion Strategy: Opening new dialysis centers and clinics across different geographies will be a primary driver of revenue growth.

Increased Healthcare Access & Awareness: Improved diagnostic capabilities and greater awareness are leading to earlier detection and treatment seeking for kidney conditions.

Government Healthcare Schemes: Initiatives like Ayushman Bharat can expand access to dialysis services for a broader population, potentially increasing patient volumes.

Risks

Intense Competition: The market is competitive with existing multi-specialty hospitals and other standalone dialysis chains, which can lead to pricing pressure.

Regulatory & Reimbursement Risk: Changes in healthcare regulations, pricing caps on medical procedures (including dialysis), or reimbursement policies from insurance providers/government schemes could impact profitability.

Talent Acquisition & Retention: Shortage of qualified nephrologists, specialized technicians, and nursing staff can pose significant operational challenges and increase labor costs.

Capital-Intensive Expansion: Establishing and equipping new dialysis centers requires substantial capital investment, which could strain finances if expansion is rapid or returns are delayed.

Technology Obsolescence: Rapid advancements in medical technology could require significant investment in upgrading equipment or adapting to new treatment methodologies.

Dependence on Medical Consumables: Fluctuations in the cost or availability of critical medical consumables and equipment required for dialysis.

Management & Ownership

Nephro Care India Ltd. is typically promoted by its founders (promoters), common for Indian companies, who often maintain a significant ownership stake and play a crucial role in strategic direction and operational management. The quality of management is critical for navigating the complex healthcare landscape, executing expansion plans, and maintaining clinical standards. Specific details on the individual promoters' background and the broader ownership structure (e.g., institutional holdings) would be available through public filings and IPO documents.

Outlook

Nephro Care India Ltd. operates in a high-demand and growing segment of the Indian healthcare market due to the increasing burden of chronic kidney disease. The specialized focus positions it well to capture this growth. The bull case rests on successful execution of its expansion strategy, maintaining high clinical standards to build brand reputation, and efficient cost management as it scales. Favorable regulatory support for dialysis services and continued increase in healthcare spending would further aid growth. The bear case involves intense competition leading to pricing pressures, challenges in attracting and retaining specialized medical talent, and potential regulatory headwinds affecting profitability. The capital-intensive nature of facility expansion also presents a financial risk if growth does not materialize as expected or if operating efficiencies are not achieved. Overall, the company's future performance will largely depend on its ability to effectively scale its operations while sustaining quality care and managing competitive and regulatory challenges.

Nephro Care India Share Price

Live · NSE · Inception: 2014
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Nephro Care India Quarterly Results

#(Fig in Cr.) Dec 2025 Mar 2026
Net Sales 23 27
Other Income 0 1
Total Income 23 28
Total Expenditure 21 25
Operating Profit 2 3
Interest 0 -0
Depreciation 1 2
Exceptional Income / Expenses 0 0
Profit Before Tax 1 1
Provision for Tax 0 0
Profit After Tax 0 1
Adjustments 0 0
Profit After Adjustments 0 1
Adjusted Earnings Per Share 0.3 0.6

Nephro Care India Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 2 3 17 27 46 50
Other Income 0 0 0 0 2 1
Total Income 2 3 17 28 48 51
Total Expenditure 2 3 14 21 40 46
Operating Profit 0 0 3 7 7 5
Interest 0 0 0 0 0 0
Depreciation 0 0 1 1 2 3
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 0 0 3 6 5 2
Provision for Tax 0 0 0 2 1 0
Profit After Tax 0 -0 2 5 4 1
Adjustments 0 0 0 -0 0 0
Profit After Adjustments 0 -0 2 4 4 1
Adjusted Earnings Per Share 4.4 -0 2.4 3.8 2.2 0.9

Nephro Care India Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 0 0 3 15 53
Minority's Interest 0 0 0 0 0
Borrowings 1 2 2 0 0
Other Non-Current Liabilities 0 0 -0 -0 1
Total Current Liabilities 0 2 3 6 14
Total Liabilities 1 5 8 21 68
Fixed Assets 0 1 3 5 31
Other Non-Current Assets 1 2 2 5 9
Total Current Assets 1 1 3 11 28
Total Assets 1 5 8 21 68

Nephro Care India Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 1 2 1
Cash Flow from Operating Activities 0 1 4 1 8
Cash Flow from Investing Activities -0 -3 -2 -8 -40
Cash Flow from Financing Activities 0 2 -0 6 35
Net Cash Inflow / Outflow 0 0 2 -1 3
Closing Cash & Cash Equivalent 0 1 2 1 5

Nephro Care India Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 4.44 -0.01 2.37 3.78 2.21
CEPS(Rs) 5.09 0.1 3.16 4.23 3.7
DPS(Rs) 0 0 0 0 0
Book NAV/Share(Rs) 0.75 0.5 2.53 12.62 32.44
Core EBITDA Margin(%) 8.47 3.67 20.04 23.75 12.76
EBIT Margin(%) 8.19 0.49 15.46 23.17 10.73
Pre Tax Margin(%) 6.46 0.01 15.08 22.85 10.49
PAT Margin (%) 4.86 -0.29 13.88 16.53 7.91
Cash Profit Margin (%) 5.57 2.97 18.47 18.47 13.25
ROA(%) 7.88 -0.34 37.08 31 8.16
ROE(%) 591.33 -3.84 156.92 51.3 10.62
ROCE(%) 21.11 0.9 65.72 62.97 14.42
Receivable days 0 20.54 2.52 1.32 13.4
Inventory Days 5.04 10.44 6.99 5.61 6.26
Payable days 94.24 96.02 51.44 56.5 79.79
PER(x) 0 0 0 0 57.61
Price/Book(x) 0 0 0 0 3.92
Dividend Yield(%) 0 0 0 0 0
EV/Net Sales(x) 0.12 0.71 0.04 0.39 4.45
EV/Core EBITDA(x) 1.36 18.94 0.19 1.55 27.7
Net Sales Growth(%) 0 87.66 399.14 59.31 69.04
EBIT Growth(%) 0 -88.76 0 138.7 -21.7
PAT Growth(%) 0 -111.05 0 89.77 -19.18
EPS Growth(%) 0 -100.22 0 59.44 -41.65
Debt/Equity(x) 46.18 5.12 0.98 0 0
Current Ratio(x) 1.08 0.66 0.89 1.86 2.01
Quick Ratio(x) 1.03 0.55 0.75 1.8 1.93
Interest Cover(x) 4.74 1.01 40.23 74.13 44.86
Total Debt/Mcap(x) 0 0 0 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +70% +148% — —
Operating Profit CAGR 0% — — —
PAT CAGR -20% — — —
Share Price CAGR -38% — — —
ROE Average +11% +73% +161% +161%
ROCE Average +14% +48% +33% +33%

Nephro Care India Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 61.71 %
FII 0.96 %
DII (MF + Insurance) 1.29 %
Public (retail) 36.03 %
Others 0.01 %
# Sep 2024 Dec 2024 Mar 2025 Sep 2025 Mar 2026 Jun 2026
Promoter 61.3861.3861.4461.4761.7161.71
FII 3.924.063.53.470.730.96
DII 4.823.412.241.041.31.29
Public 29.8731.1432.8234.0236.2736.03
Others 000000
Total 100100100100100100

Nephro Care India Peer Comparison

Hospital & Healthcare Services Edit Columns

Nephro Care India Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Nephro Care India Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 73%

Cons

  • Debtor days have increased from 56.5 to 79.79days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp